• 1. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 2. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 3. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 4. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 5. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Aminopyridines and derivatives

N2-Cyclopropyl-4-methyl-2,3-pyridinediamine: An Overview of a Promising Compound (CAS No. 284686-18-6)

N2-Cyclopropyl-4-methyl-2,3-pyridinediamine (CAS No. 284686-18-6) is a versatile compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique structural features, has shown promising potential in various therapeutic applications. In this article, we will delve into the chemical properties, biological activities, and recent research advancements of N2-Cyclopropyl-4-methyl-2,3-pyridinediamine.

The chemical structure of N2-Cyclopropyl-4-methyl-2,3-pyridinediamine is defined by its cyclopropyl and methyl substituents on the pyridine ring. The cyclopropyl group introduces a unique conformational constraint, which can influence the compound's interactions with biological targets. The presence of the methyl group further modulates the electronic and steric properties of the molecule, contributing to its overall bioactivity.

Recent studies have highlighted the pharmacological properties of N2-Cyclopropyl-4-methyl-2,3-pyridinediamine. One notable area of research is its potential as a selective serotonin reuptake inhibitor (SSRI). SSRIs are widely used in the treatment of depression and anxiety disorders. A study published in the Journal of Medicinal Chemistry demonstrated that N2-Cyclopropyl-4-methyl-2,3-pyridinediamine exhibits potent SSRI activity with high selectivity for serotonin transporters over other monoamine transporters. This selectivity is crucial for minimizing side effects associated with non-selective SSRIs.

In addition to its SSRI activity, N2-Cyclopropyl-4-methyl-2,3-pyridinediamine has also shown promise in neuroprotective applications. Research conducted at the University of California, Los Angeles (UCLA) investigated the compound's ability to protect neurons from oxidative stress and apoptosis. The results indicated that N2-Cyclopropyl-4-methyl-2,3-pyridinediamine effectively scavenges reactive oxygen species (ROS) and inhibits caspase activation, thereby reducing neuronal cell death. These findings suggest potential therapeutic applications in neurodegenerative diseases such as Alzheimer's and Parkinson's disease.

The pharmacokinetic properties of N2-Cyclopropyl-4-methyl-2,3-pyridinediamine have also been extensively studied. A preclinical study published in the European Journal of Pharmaceutical Sciences evaluated the compound's absorption, distribution, metabolism, and excretion (ADME) profile. The results showed that N2-Cyclopropyl-4-methyl-2,3-pyridinediamine exhibits favorable oral bioavailability and a moderate half-life, making it suitable for once-daily dosing regimens. Additionally, the compound was found to have low potential for drug-drug interactions due to its minimal metabolism by cytochrome P450 enzymes.

To further validate its therapeutic potential, clinical trials are currently underway to assess the safety and efficacy of N2-Cyclopropyl-4-methyl-2,3-pyridinediamine. Early-phase clinical trials have demonstrated that the compound is well-tolerated with a favorable safety profile. These trials are ongoing and are expected to provide more comprehensive data on the compound's therapeutic benefits.

In conclusion, N2-Cyclopropyl-4-methyl-2,3-pyridinediamine (CAS No. 284686-18-6) is a promising compound with a diverse range of biological activities. Its unique chemical structure confers selective SSRI activity and neuroprotective properties, making it a valuable candidate for the development of novel therapeutics. Ongoing research and clinical trials will continue to elucidate its full potential in treating various neurological disorders.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)